

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 under
the Securities Exchange Act of 1934**

For the month ended December, 2012

ICON plc
(Registrant's name)

0-29714
(Commission file number)

South County Business Park, Leopardstown, Dublin 18, Ireland
(Address of principal executive offices)

Brendan Brennan, CFO
South County Business Park Leopardstown, Dublin 18, Ireland.
Brendan.Brennan@iconplc.com
0011-353-1-291-2000

(Name, telephone number, email and/or facsimile number and address of Company contact person)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Yes No

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes No

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes No

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82 **N/A**

EXHIBIT LIST

Exhibit Description

99.1 ICON plc Press Release issued December 21, 2012.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ICON plc

Date: December 21, 2012

/s/ Brendan Brennan
Brendan Brennan
Chief Financial Officer

Mr. Thomas Lynch Elected as Chairman of ICON plc

DUBLIN--(BUSINESS WIRE)--December 21, 2012--**ICON plc, (NASDAQ: ICLR)(ISIN: IE0005711209)**, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that, Mr. Thomas Lynch has been appointed as Chairman of the board of ICON plc with effect from 1st January 2013.

Mr. Lynch has served as a Non-Executive Director of ICON since January 1996 and as Chairman of its Audit, Compensation and Nominations Committees as well as Lead Independent Director since December 2009.

Mr. Lynch served as Chairman and Chief Executive Officer of Amarin Corporation from December 2007 through December 2009 during which time he re-purposed and refinanced the company toward the development of Vascepa for hypertriglyceridemia and dislipidemia. Mr Lynch retired from the Board of Amarin in October 2010 but continues as Chairman of Amarin Pharmaceuticals Ireland Ltd.

Mr. Lynch served in a variety of senior roles in Elan Corporation plc from 1993 to 2004. He was a director of IDA Ireland from 2001-2010 and of the Royal Opera House (Covent Garden) from 2001-2010. He currently serves as a director of GW Phamaceuticals plc, is Chairman of Dublin Academic Medical Centre (an academic health science centre incorporating the College of Health Sciences UCD Dublin, St Vincent's Hospital Group and the Mater Misericordiae University Hospital); and the Queens University of Belfast Foundation. He also serves as a board member of a number of public and privately held pharmaceutical companies.

Mr. Lynch commented, "I am very pleased to assume the role of Chairman at this time of great opportunity for ICON. I would like to thank Dr. Bruce Given, my predecessor, for his contribution as Chairman over the last three years. I look forward to working with my Board colleagues and the executive team to help ICON continue to grow and enhance its position as the global partner of choice in the CRO industry."

The information contained in this release is as of 21st December 2012. The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. A description of risks and uncertainties relating to ICON and its business can be found in ICON's Annual Report for the fiscal year ended December 31, 2011 and in the forms filed with the US Securities and Exchange Commission, including the Forms 20-F, F-1, S-8 and F-3. ICON disclaims any intent or obligation to update these forward-looking statements.

About ICON plc:

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently operates from 82 locations in 40 countries and has approximately 9,430 employees. Further information is available at www.iconplc.com.

ICON/ICLR-F**CONTACT:**

ICON plc
Investor Relations
1-888-381-7923

or

Brendan Brennan
Chief Financial Officer
+353-1-291-2000

or

Sam Farthing
VP Investor Relations
+353-1-291-2000